

Paulus Kirchhof

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3296251/paulus-kirchhof-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512
papers

114,380
citations

102
h-index

337
g-index

646
ext. papers

137,641
ext. citations

6.2
avg, IF

7.41
L-index

#	Paper	IF	Citations
512	Mutation in a Family with a Strong History of Sudden Cardiac Death.. <i>Genes</i> , 2022 , 13,	4.2	
511	Disturbed lipid and amino acid metabolisms in COVID-19 patients.. <i>Journal of Molecular Medicine</i> , 2022 , 100, 555	5.5	8
510	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death.. <i>Journal of the American Heart Association</i> , 2022 , e022833	6	0
509	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration.. <i>Circulation</i> , 2022 , 145, 392-409	16.7	4
508	Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels.. <i>Journal of Molecular and Cellular Cardiology</i> , 2022 , 166, 23-35	5.8	0
507	Basic Research Approaches to Evaluate Cardiac Arrhythmia in Heart Failure and Beyond.. <i>Frontiers in Physiology</i> , 2022 , 13, 806366	4.6	0
506	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022 , 346, 19-26	3.2	0
505	Influence of severe anemia on procedural safety and one-year outcome after left atrial appendage closure: Insights from a very high-risk cohort.. <i>IJC Heart and Vasculature</i> , 2022 , 38, 100946	2.4	
504	Simultaneous Whole-Chamber Non-contact Mapping of Highest Dominant Frequency Sites During Persistent Atrial Fibrillation: A Prospective Ablation Study.. <i>Frontiers in Physiology</i> , 2022 , 13, 826449	4.6	
503	High resolution optical mapping of cardiac electrophysiology in pre-clinical models.. <i>Scientific Data</i> , 2022 , 9, 135	8.2	0
502	The Atrial Fibrillation Heart Team-guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence.. <i>European Heart Journal</i> , 2022 , 43, 1691-1692	9.5	0
501	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024932	6	2
500	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1932-1948	15.1	5
499	A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. <i>Biomolecules</i> , 2021 , 11,	5.9	2
498	Cytokine-Mediated Alterations of Human Cardiac Fibroblast's Secretome. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
497	In Patients With Recently Diagnosed Atrial Fibrillation, Think Anticoagulation and Rhythm Control. <i>Circulation</i> , 2021 , 144, 1587-1589	16.7	0
496	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. <i>Cardiovascular Research</i> , 2021 ,	9.9	4

495	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. <i>Data in Brief</i> , 2021 , 39, 107451	1.2	1
494	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021 , 23, 329-344	3.9	14
493	Sex differences in patients with cardiogenic shock. <i>ESC Heart Failure</i> , 2021 , 8, 1775-1783	3.7	3
492	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 902-908	5.1	3
491	CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1757-1769	6.1	3
490	The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillation-a dedication to Harry Crijns. <i>Europace</i> , 2021 , 23, ii34-ii39	3.9	1
489	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021 , 84, 485-490	2.8	1
488	Heart failure in adults with congenital heart disease: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 529-537	2.6	2
487	Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	0
486	Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how?. <i>Cardiovascular Research</i> , 2021 , 117, 1718-1731	9.9	1
485	Regulation of basal and norepinephrine-induced cAMP and I in hiPSC-cardiomyocytes: Effects of culture conditions and comparison to adult human atrial cardiomyocytes. <i>Cellular Signalling</i> , 2021 , 82, 109970	4.9	2
484	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation Network (AFNET). <i>Europace</i> , 2021 , 23, 1903-1912	3.9	1
483	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006852	5.8	3
482	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021 , 110, 938-958	6.1	1
481	Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. <i>Lancet Neurology</i> , 2021 , 20, 426-436	24.1	13
480	Mobile health for walking on the tightrope of optimal physical activity to reduce the risk of atrial fibrillation. <i>European Heart Journal</i> , 2021 , 42, 2484-2486	9.5	2
479	Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone. <i>Heart Rhythm</i> , 2021 , 18, 1212-1220	6.7	2
478	The additive prognostic value of coronary calcium score (CCS) to single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI)-real world data from a single center. <i>Journal of Nuclear Cardiology</i> , 2021 , 28, 2086-2096	2.1	4

477	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 229-237	4.6	6
476	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f30-f39	6.4	10
475	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)	9.5	1676
474	Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021 , 16, 591-599	3.7	3
473	Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 10760296211021171	3.3	1
472	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , 2021 , 76, 431-439	0.9	
471	Effects of genetic background, sex, and age on murine atrial electrophysiology. <i>Europace</i> , 2021 , 23, 958-969	3.6	3
470	Anticoagulation management in adult patients with congenital heart disease: a narrative review.. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 1324-1333	2.6	1
469	Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease-a 10-year, single-center experience.. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 1344-1355	2.6	1
468	Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. <i>PLoS Medicine</i> , 2021 , 18, e1003405	11.6	1
467	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
466	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2021 , 8, 1295-1303	3.7	9
465	CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
464	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2021 ,	9.5	10
463	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. <i>European Journal of Heart Failure</i> , 2021 , 23, 1942-1951	12.3	4
462	Applying the ESC 2016, H FPEF, and HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. <i>ESC Heart Failure</i> , 2021 , 8, 3603-3612	3.7	4
461	OCEAN Trial Update. <i>American Heart Journal</i> , 2021 ,	4.9	
460	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2021 , 144, 845-858	16.7	14

459	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. <i>Critical Care</i> , 2021 , 25, 325	10.8	0
458	Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA-R). <i>ESC Heart Failure</i> , 2021 ,	3.7	1
457	Reply to the Editor-From AFFIRM to EAST-Better rhythm control and general AF management explain differences in outcomes. <i>Heart Rhythm</i> , 2021 , 18, 1814	6.7	
456	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention-Prevalence, Risk factors, and Predictors of Outcome. <i>American Journal of Cardiology</i> , 2021 , 157, 22-32	3	1
455	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 604-612	4.3	12
454	A tale of two countries: how decentralized organization and long-term investment build resilient healthcare systems. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 201-203	4.6	5
453	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020 , 318, 67-73	3.2	4
452	The Amplitude-Normalized Area of a Bipolar Electrogram as a Measure of Local Conduction Delay in the Heart. <i>Frontiers in Physiology</i> , 2020 , 11, 465	4.6	2
451	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. <i>Europace</i> , 2020 , 22, 1026-1035	3.9	12
450	Clinical Potential of Targeting Fibroblast Growth Factor-23 and Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020 , 9, e016041	6	11
449	Epigenetic and Transcriptional Networks Underlying Atrial Fibrillation. <i>Circulation Research</i> , 2020 , 127, 34-50	15.7	22
448	Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. <i>Journal of the American Heart Association</i> , 2020 , 9, e009530	6	10
447	Begleitmedikation bei Therapie mit direkten oralen Antikoagulanzen. <i>Kardiologe</i> , 2020 , 14, 29-31	0.6	
446	Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VerT Trial. <i>TH Open</i> , 2020 , 4, e20-e32	2.7	9
445	Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. <i>Europace</i> , 2020 , 22, 1149-1161	3.9	19
444	Self-palpation for detection of paroxysmal atrial fibrillation: Much noise with little signal. <i>PLoS Medicine</i> , 2020 , 17, e1003098	11.6	1
443	Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. <i>Europace</i> , 2020 , 22, 748-760	3.9	20
442	Automatic Holter electrocardiogram analysis in ischaemic stroke patients to detect paroxysmal atrial fibrillation: ready to replace physicians?. <i>European Journal of Neurology</i> , 2020 , 27, 1272-1278	6	6

441	Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. <i>JCI Insight</i> , 2020 , 5,	9.9	12
440	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020 , 7, 1-42	1.7	0
439	Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a two-centre, double-blind, randomised controlled trial in young children undergoing cardiac surgery. <i>BMJ Open</i> , 2020 , 10, e042176	3	1
438	Intermittent Optogenetic Tachypacing of Atrial Engineered Heart Tissue Induces Only Limited Electrical Remodelling. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 77, 291-299	3.1	3
437	Temporal irregularity quantification and mapping of optical action potentials using wave morphology similarity. <i>Progress in Biophysics and Molecular Biology</i> , 2020 , 157, 84-93	4.7	3
436	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020 , 22, 250-258	3.9	2
435	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. <i>Circulation</i> , 2020 , 142, 2095-2106	16.7	83
434	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. <i>Clinical Cardiology</i> , 2020 , 43, 1405-1413	3.3	2
433	Integrated care in stroke survivors: When and how much?. <i>EclinicalMedicine</i> , 2020 , 25, 100489	11.3	0
432	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. <i>Heart</i> , 2020 , 106, 1919-1926	5.1	6
431	Trusting our cardiology trainees. <i>European Heart Journal</i> , 2020 , 41, 3601-3602	9.5	0
430	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectiveness-Authors' reply. <i>Europace</i> , 2020 , 22, 1602	3.9	
429	Biomarkers Associated With Aortic Valve Calcification: Should We Focus on Sex Specific Processes?. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 604	5.7	4
428	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. <i>Europace</i> , 2020 , 22, 1337-1344	3.9	5
427	Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. <i>JAMA Cardiology</i> , 2020 , 5, 1281-1285	16.2	371
426	Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heart-lung transplantation in the Eurotransplant region. <i>Journal of Heart and Lung Transplantation</i> , 2020 , 39, 1238-1249	5.8	3
425	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020 , 41, 3605-3692	9.5	12
424	Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables. <i>Open Heart</i> , 2020 , 7,	3	3

423	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020 , 383, 1305-1316	59.2	337
422	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016239	6	7
421	Mortality Prediction of the CHADS-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
420	Novel Wide-Band Dielectric Imaging System and Occlusion Tool to Guide Cryoballoon-Based Pulmonary Vein Isolation: Feasibility and First Insights. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e009219	6.4	5
419	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2497-2508	27.4	35
418	Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a two-centre, double-blind, randomised controlled trial in young children undergoing cardiac surgery 2020 , 10, e042176		1
417	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019 , 42, 1147-1154	3.3	8
416	Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. <i>Systematic Reviews</i> , 2019 , 8, 221	3	2
415	Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems. <i>American Journal of Physiology - Cell Physiology</i> , 2019 , 317, C1256-C1267	5.4	10
414	The National Institute for Health Research (NIHR) Global Health Research Group on Atrial Fibrillation management. <i>European Heart Journal</i> , 2019 , 40, 3005-3007	9.5	2
413	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019 , 132, 749-757.e5	2.4	34
412	Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 120	2.3	6
411	The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients. <i>American Journal of Medicine</i> , 2019 , 132, 921-925	2.4	7
410	High-Throughput Analysis of Optical Mapping Data Using ElectroMap. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	7
409	Education as a vehicle towards quality improvement in the European Society of Cardiology. <i>Cardiovascular Research</i> , 2019 , 115, e80-e81	9.9	
408	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , 2019 , 21, 690-693	12.3	2
407	MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 58	2.3	3
406	Cardiac Optogenetics and Optical Mapping - Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology. <i>Frontiers in Physiology</i> , 2019 , 10, 182	4.6	23

405	ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology. <i>Scientific Reports</i> , 2019 , 9, 1389	4.9	33
404	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019 , 9, e022478	3	29
403	Digital learning and the future cardiologist. <i>European Heart Journal</i> , 2019 , 40, 499-501	9.5	6
402	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019 , 21, 421-427	3.9	2
401	Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?. <i>Europace</i> , 2019 , 21, 181-183	3.9	3
400	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. <i>Europace</i> , 2019 , 21, 1459-1467	3.9	24
399	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 165	2.3	16
398	Effect of Concomitant Atrial Fibrillation on In-Hospital Outcomes of Non-ST-Elevation-Acute Coronary Syndrome-Related Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2019 , 124, 465-475	3	8
397	Evidence for Arrhythmogenic Effects of A-Adenosine Receptors. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1051	5.6	9
396	Second look Holter ECG in neurorehabilitation. <i>Neurological Research and Practice</i> , 2019 , 1, 41	3.2	0
395	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. <i>European Heart Journal</i> , 2019 , 40, 3793-3799c	9.5	29
394	Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2019 , 140, 1834-1850	16.7	93
393	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. <i>European Heart Journal</i> , 2019 , 40, 1728-1738	9.5	3
392	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 70-79	6.4	20
391	Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 97-104	1.9	13
390	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019 , 40, 1268-1276	9.5	67
389	Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. <i>Neurology</i> , 2019 , 92, e115-e124	6.5	21
388	The future of continuing medical education: the roles of medical professional societies and the health care industry. <i>European Heart Journal</i> , 2019 , 40, 1720-1727	9.5	8

387	Stratified prevention: opportunities and limitations. Report on the 1st interdisciplinary cardiovascular workshop in Augsburg. <i>Clinical Research in Cardiology</i> , 2018 , 107, 193-200	6.1	10
386	Is there a CASTLE-AF on the hill?. <i>European Heart Journal</i> , 2018 , 39, 1324-1325	9.5	3
385	Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation. <i>Cardiovascular Research</i> , 2018 , 114, 1313-1323	9.9	11
384	Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. <i>European Heart Journal</i> , 2018 , 39, 2959-2971	9.5	97
383	The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy. <i>European Heart Journal</i> , 2018 , 39, 2997-2999	9.5	3
382	European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. <i>Europace</i> , 2018 , 20, 225-233	3.9	70
381	Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?. <i>European Heart Journal</i> , 2018 , 39, 450-452	9.5	1
380	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018 , 197, 124-132	4.9	27
379	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018 , 20, 395-407	3.9	66
378	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018 , 265, 141-147	3.2	26
377	Expert opinion paper on atrial fibrillation detection after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2018 , 107, 871-880	6.1	45
376	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018 , 39, 2942-2955	9.5	121
375	Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. <i>Heart</i> , 2018 , 104, 1608-1614	5.1	10
374	Editor's Choice- Practical challenges regarding in-hospital telemetry monitoring require the development of European practice standards. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 774-776	4.3	2
373	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018 , 20, e87-e95	3.9	11
372	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 74-84	2.7	14
371	Innovations in Antiarrhythmic Drug Therapy 2018 , 1076-1083		
370	Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. <i>Europace</i> , 2018 , 20, 1612-1620	3.9	17

369	Phenotyping of Mice with Heart Specific Overexpression of A-Adenosine Receptors: Evidence for Cardioprotective Effects of A-Adenosine Receptors. <i>Frontiers in Pharmacology</i> , 2018 , 9, 13	5.6	12
368	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018 , 50, 1225-1233	36.3	277
367	Positionspapier zur Detektion von Vorhofflimmern nach ischämischen Schlaganfall. <i>Aktuelle Neurologie</i> , 2018 , 45, 93-106		9
366	Outcome of left atrial appendage occlusion in high-risk patients. <i>Heart</i> , 2018 , 104, 594-599	5.1	11
365	The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018 , 11, 2058	0.8	10
364	Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2546-2547	15.1	
363	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1984-1986	15.1	9
362	Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. <i>BMJ Open</i> , 2018 , 8, e022690	3	22
361	Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	9
360	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 141-153	15.1	35
359	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. <i>International Journal of Cardiology</i> , 2018 , 270, 160-166	3.2	15
358	Catheter ablation in patients with persistent atrial fibrillation. <i>European Heart Journal</i> , 2017 , 38, 20-26	9.5	75
357	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 409-419	15.1	46
356	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 50.e1-50.e84	1.5	6
355	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017 , 232, 98-104	3.2	13
354	PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>Journal of Physiology</i> , 2017 , 595, 4019-4026	3.9	32
353	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017 , 103, 1024-1030	5.1	66
352	Patient-centred care of patients with ventricular arrhythmias and risk of sudden cardiac death: What do the 2015 European Society of Cardiology guidelines add?. <i>European Journal of Cardiovascular Nursing</i> , 2017 , 16, 558-564	3.3	1

351	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2017 , 135, 1851-1867	16.7	302
350	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <i>American Heart Journal</i> , 2017 , 190, 12-18	4.9	143
349	The future of atrial fibrillation management: integrated care and stratified therapy. <i>Lancet, The</i> , 2017 , 390, 1873-1887	4.0	81
348	Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern. <i>Kardiologie</i> , 2017 , 11, 193-204	0.6	11
347	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. <i>Europace</i> , 2017 , 19, 132-138	3.9	24
346	Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 157-162	6.4	12
345	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 50	0.7	124
344	44 Diagnostic yield of 7-day holter ecg monitoring for new af and association with comorbidities. outcomes in an all-comer cohort from a large teaching trust. <i>Heart</i> , 2017 , 103, A35-A36	5.1	
343	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017 , 38, 2137-2149	9.5	162
342	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859	9.5	50
341	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017 , 38, 860-868	9.5	75
340	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017 , 7, e015099	3	29
339	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017 , 6,	6	93
338	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. <i>Netherlands Heart Journal</i> , 2017 , 25, 551-558	2.2	20
337	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. <i>Nature Reviews Cardiology</i> , 2017 , 14, 701-714	14.8	61
336	Kommentar zu den ESC-Leitlinien 2015 ¶entrikul¶e Arrhythmien und Pr¶vention des pl¶zlichen Herztodes¶ <i>Kardiologie</i> , 2017 , 11, 27-43	0.6	8
335	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , 19, 9-42	12.3	189
334	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017 , 19, 169-179	3.9	58

333	Training the next generation of cardiovascular leaders in health policy and economics. <i>European Heart Journal</i> , 2017 , 38, 3332-3335	9.5	1
332	188 Development of a novel software package for high-throughput processing and analysis of cardiac optical mapping data. <i>Heart</i> , 2017 , 103, A128.2-A129	5.1	
331	221 Altered biophysical properties of the voltage-gated sodium channels in mouse atrial and ventricular cardiomyocytes. <i>Heart</i> , 2017 , 103, A143.3-A144	5.1	
330	83 Use of feature tracking to assess systemic right ventricles in congenital heart disease patients with both single and dual ventricular circulations. <i>Heart</i> , 2017 , 103, A60.2-A62	5.1	1
329	Recent advances in rhythm control for atrial fibrillation. <i>F1000Research</i> , 2017 , 6, 1796	3.6	8
328	NOACs in Atrial Fibrillation. <i>European Heart Journal</i> , 2017 , 38, 2382-2385	9.5	2
327	ESC Apps for Atrial Fibrillation. <i>European Heart Journal</i> , 2017 , 38, 2643-2645	9.5	8
326	Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. <i>Europace</i> , 2017 , 19, 921-928	3.9	3
325	Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. <i>American Heart Journal</i> , 2016 , 172, 19-25	4.9	23
324	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Respiratory Society Guidelines (AERS), International Society for Heart and Lung Transplantation (ISHLT), and the American Society of Echocardiography (ASE). <i>European Heart Journal</i> , 2016 , 37, 267-315	9.5	3455
323	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 267-315	9.5	3850
322	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1145-53	9.5	319
321	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016 , 37, 747-54	9.5	46
320	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465
319	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016 , 37, 2999-3058	9.5	1781
318	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	3.9	1293
317	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 2768-2801	9.5	1249
316	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. <i>Clinical Cardiology</i> , 2016 , 39, 565-569	3.3	27

315	PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1881-1894	15.1	50
314	'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 2853	9.5	27
313	Effect of age and sex on efficacy and tolerability of beta-blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016 , 353, i1855	5.9	62
312	170 Plakoglobin Deficiency Predisposes to Left Atrial Electrical Remodeling Following Chronic Exposure to Anabolic Steroids. <i>Heart</i> , 2016 , 102, A119-A119	5.1	
311	217 Differences in Blood Biomarker Composition Between Paroxysmal AF and Sinus Rhythm Patients, Without Heart Failure. <i>Heart</i> , 2016 , 102, A143.2-A144	5.1	
310	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular	3.9	445
309	Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. <i>Nature Reviews Cardiology</i> , 2016 , 13, 230-248	14.8	97
308	Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VerT trial. <i>Europace</i> , 2016 , 18, 184-90	3.9	27
307	Almanac 2015: atrial fibrillation research in Heart. <i>Heart</i> , 2016 , 102, 573-80	5.1	2
306	Guía ESC 2015 sobre el tratamiento de pacientes con arritmias ventriculares y prevención de la muerte súbita cardíaca. <i>Revista Española De Cardiología</i> , 2016 , 69, 176.e1-176.e77	1.5	11
305	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Revista Española De Cardiología (English Ed)</i> , 2016 , 69, 176	0.7	30
304	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Española De Cardiología</i> , 2016 , 69, 177.e1-177.e62	1.5	137
303	Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa. <i>Revista Española De Cardiología</i> , 2016 , 69, 69.e1-69.e49	1.5	5
302	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , 2016 , 203, 660-6	3.2	116
301	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016 , 18, 37-50	3.9	90
300	An update on atrial fibrillation in 2014: From pathophysiology to treatment. <i>International Journal of Cardiology</i> , 2016 , 203, 22-9	3.2	45
299	A Regional Reduction in Ito and IKACH in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity. <i>PLoS ONE</i> , 2016 , 11, e0154077	3.7	21
298	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <i>American Heart Journal</i> , 2016 , 179, 59-68	4.9	29

297	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2016 , 69, 1167.e1-1167.e85	1.5	91
296	Improved exercise tolerance in patients with Preserved Ejection fraction by Spironolactone on myocardial fibrosis in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e012241	3	10
295	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016 , 2, 299-305	4.6	23
294	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). <i>European Heart Journal</i> , 2016 , 37, 2313-2318	9.5	3919
293	Can biomarkers balance stroke and bleeding risk?. <i>Lancet, The</i> , 2016 , 387, 2266-2268	40	4
292	Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2016 , 69, 939.e1-939.e87	1.5	10
291	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , 50, e1-e88	3	589
290	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2016 , 18, 891-975	12.3	4036
289	26 Digoxin (Friend or Foe? A Comprehensive Review of Digoxin use and Mortality. <i>Heart</i> , 2015 , 101, A14.2-A15	5.1	1
288	Diagnostik und Behandlung von Vorhofflimmern. <i>CME (Berlin, Germany)</i> , 2015 , 12, 49-57	0	
287	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology	3.9	426
286	168 Atrial arrhythmias and electrical remodelling after endurance training in a mouse model of arrhythmogenic right ventricular cardiomyopathy. <i>Heart</i> , 2015 , 101, A95.2-A96	5.1	
285	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry. <i>BMC Neurology</i> , 2015 , 15, 129	3.1	16
284	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2015 , 17, 1102-1114	3.9	123
283	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology	9.5	2187
282	2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2015 , 36, 2921-2964	9.5	1102
281	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
280	The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. <i>Europace</i> , 2015 , 17, 1457-66	3.9	4

279	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015 , 351, h4451	5.9	172
278	2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>European Heart Journal</i> , 2015 , 36, 3075-3128	9.5	2465
277	First report on an inotropic peptide activating tetrodotoxin-sensitive, "neuronal" sodium currents in the heart. <i>Circulation: Heart Failure</i> , 2015 , 8, 79-88	7.6	3
276	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 386	4.3	8
275	YIA5 Plakoglobin Deficiency Leads to Increased Biventricular Beta-Catenin Expression in the Murine Heart. <i>Heart</i> , 2015 , 101, A124.1-A124	5.1	
274	YIA3 Regional Action Potential Gradients in the Murine Left Atrium. <i>Heart</i> , 2015 , 101, A123.1-A123	5.1	
273	Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis--data from the German Competence Network on Atrial Fibrillation. <i>Europace</i> , 2015 , 17, 1354-62	3.9	28
272	The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>European Heart Journal</i> , 2015 , 36, 255-6	9.5	19
271	Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK. <i>BMJ Open</i> , 2015 , 5, e009267	3	14
270	Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. <i>Kidney International</i> , 2015 , 87, 200-9	9.9	19
269	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study. <i>International Journal of Cardiology</i> , 2015 , 183, 105-10	3.2	14
268	Universal cardiac induction of human pluripotent stem cells in two and three-dimensional formats: implications for in vitro maturation. <i>Stem Cells</i> , 2015 , 33, 1456-69	5.8	64
267	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>EuroIntervention</i> , 2015 , 10, 1095-108	3.1	25
266	The heart and brain imaging in lone atrial fibrillation - are we surprised?. <i>Current Pharmaceutical Design</i> , 2015 , 21, 613-21	3.3	
265	169 PITX2C deficiency augments the anti-arrhythmic properties of flecainide: results in a mouse model and validation in a human atrium simulation study. <i>Heart</i> , 2015 , 101, A96.1-A96	5.1	
264	Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants. <i>Europace</i> , 2014 , 16, 149-50	3.9	3
263	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 136.e1-136.e56	1.5	8
262	Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTtrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. <i>American Heart Journal</i> , 2014 , 167, 646-52	4.9	22

261	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014 , 16, 308-19	3.9	224
260	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. <i>European Heart Journal</i> , 2014 , 35, 3346-55	9.5	278
259	Treatment Satisfaction In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With Pact-Q2 At Baseline And 12-Month Follow-Up: Prefer In Af Registry. <i>Value in Health</i> , 2014 , 17, A497-3	3.3	1
258	Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry. <i>Value in Health</i> , 2014 , 17, A473	3.3	0
257	New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. <i>Europace</i> , 2014 , 16, 1092-8	3.9	39
256	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2733-79	9.5	2361
255	Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. <i>Lancet, The</i> , 2014 , 384, 2235-43	4.0	323
254	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	33
253	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European	9.5	3467
252	Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2014 , Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014 , 100, 1625-35	5.1	20
251	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , 2014 , 35, 2001-9	9.5	199
250	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2873-92	9.5	2334
249	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Heart Rhythm</i> , 2014 , 11, e166-96	6.7	179
248	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the	9.5	413
247	Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society. <i>European Heart Journal</i> , 2014 , 35, 3153-9	9.5	3
246	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Europace</i> , 2014 , 16, 1257-83	3.9	135
245	Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trials. <i>Europace</i> , 2014 , 16, 812-9	3.9	37
244	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014 , 16, 1655-73	3.9	77

243	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014 , 35, 3033-69, 3069a-3069k	9.5	1974
242	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 135.e1-135.e81	1.5	9
241	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014 , 35, 1448-56	9.5	128
240	Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Circulation Journal</i> , 2014 , 78, 2674-81	2.9	19
239	199 Pitx2c Deficiency May Increase the Antiarrhythmic Properties of Flecainide. <i>Heart</i> , 2014 , 100, A109.2-A110	5.1	110
238	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014 , 10, 425-34	4.4	23
237	205 Atrial Arrhythmia Susceptibility in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Heart</i> , 2014 , 100, A112.2-A113	5.1	1
236	191 Advancement of Optical Mapping through Automated Algorithms and Second Generation CMOS Detectors to Reveal Murine Atrial Activation Patterns and Regional Variation of Action Potential Duration. <i>Heart</i> , 2014 , 100, A106.1-A106	5.1	
235	Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 833-41	7	77
234	Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. <i>Europace</i> , 2014 , 16, 787-96	3.9	61
233	Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. <i>Evidence-Based Medicine</i> , 2014 , 19, 222-3		14
232	An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials. <i>Progress in Biophysics and Molecular Biology</i> , 2014 , 115, 340-8	4.7	17
231	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events--European Registry in Atrial Fibrillation (PREFER in AF). <i>Europace</i> , 2014 , 16, 6-14	3.9	283
230	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. <i>European Heart Journal</i> , 2014 , 35, 3250-7	9.5	66
229	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>BMJ Open</i> , 2014 , 4, e004700	3	12
228	The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. <i>Europace</i> , 2014 , 16, 965-72	3.9	88
227	Author reply: To PMID 23625942. <i>Europace</i> , 2014 , 16, 151-2	3.9	1
226	Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). <i>European Heart Journal</i> , 2014 , 35, 3365-76	9.5	161

225	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Journal of</i>	3	588
224	One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. <i>Clinical Cardiology</i> , 2014 , 37, 357-64	3.3	76
223	Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. <i>Clinical Cardiology</i> , 2014 , 37, 277-84	3.3	19
222	Grupo de Trabajo Conjunto sobre cirugía no cardíaca: Evaluación y manejo cardiovascular de la Sociedad Europea de Cardiología (ESC) y la European Society of Anesthesiology (ESA). <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 1052.e1-1052.e43	1.5	3
221	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , 2014 , 35, 2383-431	9.5	849
220	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014 , 23, 3-16	1.7	474
219	Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives. <i>Heart</i> , 2014 , 100, 1408-13	5.1	25
218	New Antiarrhythmic Drugs and New Concepts for Old Drugs 2014 , 1111-1119		
217	To the Editor--Propranolol, a β -adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect. <i>Heart Rhythm</i> , 2014 , 11, e1	6.7	5
216	Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?. <i>Current Vascular Pharmacology</i> , 2014 , 12, 373-83	3.3	1
215	Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013 , 386, 227-38	3.4	9
214	Kommentar: Fokus Update der Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des Vorhofflimmerns. <i>Kardiologe</i> , 2013 , 7, 171-180	0.6	4
213	Overexpression of cAMP-response element modulator causes abnormal growth and development of the atrial myocardium resulting in a substrate for sustained atrial fibrillation in mice. <i>International Journal of Cardiology</i> , 2013 , 166, 366-74	3.2	38
212	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Hipertension Y Riesgo Vascular</i> , 2013 , 30, 4-91	0.5	7
211	Flecainide acetate for the treatment of atrial and ventricular arrhythmias. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 347-57	4	17
210	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/American College of Chest Physicians with the Canadian Cardiovascular Society/European Heart Rhythm Association/American College of Chest Physicians. <i>Journal of Intensive Care Medicine</i> , 2013 , 28, 303-11	9.5	51
209	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2013 , 34, 3035-87	9.5	1444
208	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETWORK/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013 , 15, 1540-56	3.9	101

207	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, E864-70	2.7	17
206	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>American Heart Journal</i> , 2013 , 166, 442-8	4.9	102
205	Guía de práctica clínica sobre el tratamiento de las valvulopatías (versión 2012). <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 131.e1-131.e42	1.5	
204	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013 , 15, 625-51	3.9	622
203	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012: Actualización de las guías de la Sociedad Europea de Cardiología (ESC) para el manejo de la fibrilación auricular de 2010 Elaborada en colaboración con la Asociación Europea del Ritmo Cardíaco. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 54.e1-54.e24	1.5	10
202	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 880.e1-880.e64	1.5	13
201	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 53.e1-53.e46	1.5	17
200	Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial. <i>International Journal of Cardiology</i> , 2013 , 168, 3977-81	3.2	13
199	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2013 , 22, 193-278	1.7	286
198	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. <i>Europace</i> , 2013 , 15, 1389-406	3.9	379
197	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
196	Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. <i>Stroke</i> , 2013 , 44, 3357-64	6.7	152
195	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2013 , 34, 2949-3003	9.5	3076
194	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2013 , 34, 1869-74	9.5	59
193	'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply. <i>Europace</i> , 2013 , 15, 460-1	3.9	
192	Questionable levels of evidence in new atrial fibrillation guidelines? Reply. <i>Europace</i> , 2013 , 15, 461-2	3.9	
191	Tachycardia detection performance of implantable loop recorders: results from a large 'real-life' patient cohort and patients with induced ventricular arrhythmias. <i>Europace</i> , 2013 , 15, 1215-22	3.9	22
190	Prevalence of unknown atrial fibrillation in patients with risk factors. <i>Europace</i> , 2013 , 15, 657-62	3.9	45

189	2012 focused update of the ESC Guidelines for the management of atrial fibrillation [Eur Heart J (2012); 33(21):2719-2747]. <i>European Heart Journal</i> , 2013 , 34, 790-790	9.5	11
188	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013 , 31, 1281-357	1.9	3363
187	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). <i>European Heart Journal</i> , 2013 , 34, 2281-329	9.5	1491
186	EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013 , 34, 2094-106	9.5	281
185	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary. <i>Arrhythmia and Electrophysiology Review</i> , 2013 , 2, 115-9	3.2	2
184	Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. <i>Kardiologia Polska</i> , 2013 , 71, 27-118	0.9	3
183	Kommentar zu den Leitlinien der ESC zum Vorhofflimmern. <i>Kardiologe</i> , 2012 , 6, 12-27	0.6	7
182	The European Network for Translational Research in Atrial Fibrillation. <i>Clinical Investigation</i> , 2012 , 2, 1061-1067		
181	Ectopic thyroid mass in the heart. <i>Lancet, The</i> , 2012 , 379, 1762	4.0	7
180	Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. <i>Lancet, The</i> , 2012 , 380, 238-46	4.0	113
179	Venice Chart international consensus document on atrial fibrillation ablation: 2011 update. <i>Journal of Cardiovascular Electrophysiology</i> , 2012 , 23, 890-923	2.7	65
178	Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2012 , 23, 186-95	0.8	12
177	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. <i>Europace</i> , 2012 , 14, 528-606	3.9	1160
176	Gene construction, expression and functional testing of an inotropic peptide from the venom of the black scorpion <i>Hottentotta judaicus</i> . <i>Toxicon</i> , 2012 , 60, 1415-27	2.8	3
175	Antiarrhythmic drug treatment after cardioversion of atrial fibrillation [Authors' reply. <i>Lancet, The</i> , 2012 , 380, 1468	4.0	
174	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in collaboration with the European Heart Rhythm Association (EHRA) and the European Association of Cardiovascular Imaging (EACVI). <i>Journal of Intensive Care Medicine</i> , 2012 , 27, 100-110	6.7	1314
173	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2012 , 33, 1635-701	9.5	2797
172	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) † Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). [Eur Heart J 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. <i>European Heart Journal</i> , 2012 , 33, 2126-2126	9.5	15

171	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , 2012 , 14, 1385-413	3.9	1019
170	Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. <i>Stroke</i> , 2012 , 43, 2689-94	6.7	154
169	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012 , 33, 2451-96	9.5	2866
168	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
167	Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. <i>Cardiovascular Research</i> , 2012 , 95, 317-26	9.9	28
166	Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Journal of Cardio-thoracic Surgery</i> , 2012 , 42, 51-111	3	1002
165	A proposal for new clinical concepts in the management of atrial fibrillation. <i>American Heart Journal</i> , 2012 , 164, 292-302.e1	4.9	39
164	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
163	Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. <i>Progress in Biophysics and Molecular Biology</i> , 2012 , 110, 340-6	4.7	19
162	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 938.e1-938.e59	1.5	27
161	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
160	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012 , 33, 171-257	2.4	250
159	Proarrhythmia in a non-failing murine model of cardiac-specific Na ⁺ /Ca ²⁺ exchanger overexpression: whole heart and cellular mechanisms. <i>Basic Research in Cardiology</i> , 2012 , 107, 247	11.8	31
158	ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). <i>Annals of Noninvasive Electrocardiology</i> , 2012 , 17, 36-56	1.5	21
157	An introduction to murine models of atrial fibrillation. <i>Frontiers in Physiology</i> , 2012 , 3, 296	4.6	52
156	Third universal definition of myocardial infarction. <i>Circulation</i> , 2012 , 126, 2020-35	16.7	2259
155	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1787-847	9.5	3691
154	Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 43-51	6.4	121

153	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
152	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 2551-67	9.5	2064
151	Left atrial catheter ablation and ischemic stroke. <i>Stroke</i> , 2012 , 43, 265-70	6.7	52
150	Bleeding risk assessment and management in atrial fibrillation patients. <i>European Heart Journal</i> , 2012 , 33, 147-9	9.5	4
149	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012 , 14, 8-27	3.9	156
148	ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). <i>Europace</i> , 2012 , 14, 278-93	3.9	124
147	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [<i>Europace</i> 2011;13:1077-109, doi: 10.1093/europace/eur245]. <i>Europace</i> , 2012 , 14, 277-277	3.9	1
146	Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1119-30	15.9	98
145	Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 740-50	15.1	86
144	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 1012-9	7	60
143	Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 1010-23	7	56
142	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 997-1011	7	184
141	Corrigendum to: Guidelines for the management of atrial fibrillation [<i>European Heart Journal</i> (2010) 31, 2369-2429 and <i>EP-Europace</i> (2010) 12, 1360-1420]. <i>European Heart Journal</i> , 2011 , 32, 1172-1172	9.5	3
140	Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. <i>Clinical Research in Cardiology</i> , 2011 , 100, 897-905	6.1	73
139	Insights into sick sinus syndrome from an inducible mouse model. <i>Cardiovascular Research</i> , 2011 , 90, 38-48	9.9	35
138	Management of patients with palpitations: a position paper from the European Heart Rhythm Association. <i>Europace</i> , 2011 , 13, 920-34	3.9	77
137	Right atrial scar detection after catheter ablation: Comparison of 2D and high spatial resolution 3D-late enhancement magnetic resonance imaging. <i>Academic Radiology</i> , 2011 , 18, 488-94	4.3	6
136	Does omega-3 fatty acid supplementation prevent atrial fibrillation, and if so, which type?. <i>Heart Rhythm</i> , 2011 , 8, 569-70	6.7	

135	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. <i>Europace</i> , 2011 , 13, 1063-76	3.9	7
134	Moderne Diagnostik und Schlaganfallprävention bei Vorhofflimmern. <i>Aktuelle Neurologie</i> , 2011 , 38, 58-67		
133	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. <i>Europace</i> , 2011 , 13, 1517-25	3.9	41
132	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2011 , 13, 1058-1058	3.9	3
131	PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 123-33		207
130	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. <i>Cardiovascular Research</i> , 2011 , 92, 67-74	9.9	64
129	A real-time tip manometer for radiofrequency catheter ablation: new toy or useful tool?. <i>Europace</i> , 2011 , 13, 159-60	3.9	
128	Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. <i>Europace</i> , 2011 , 13, 1166-73	3.9	27
127	What are the costs of atrial fibrillation?. <i>Europace</i> , 2011 , 13 Suppl 2, ii9-12	3.9	22
126	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011 , 13, 723-46	3.9	166
125	Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. <i>Physiological Reviews</i> , 2011 , 91, 265-325	47.9	785
124	Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. <i>PLoS ONE</i> , 2011 , 6, e26389	3.7	60
123	Endovascular extraction of a coronary stent: resolution of a cathlab nightmare. <i>EuroIntervention</i> , 2011 , 7, 1008	3.1	2
122	Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 106, 263-8	3.1	24
121	Routine data from hospital information systems can support patient recruitment for clinical studies. <i>Clinical Trials</i> , 2010 , 7, 183-9	2.2	47
120	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010 , 31, 1711-9	9.5	179
119	Atrial fibrillation: Ablation of atrial fibrillation: for whom and how?. <i>Heart</i> , 2010 , 96, 1325-30	5.1	3
118	Cardiac overexpression of the human 5-HT4 receptor in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H788-98	5.2	29

117	Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. <i>Cardiovascular Research</i> , 2010 , 87, 60-72	9.9	47
116	EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. <i>Europace</i> , 2010 , 12, 1480-9	3.9	135
115	Cell-based therapy of the failing heart: a need to connect for proper electrical and contractile function. <i>Europace</i> , 2010 , 12, 1520-1	3.9	
114	MRI of right atrial function after catheter ablation of atrial flutter. <i>Academic Radiology</i> , 2010 , 17, 856-61	4.3	2
113	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. <i>Heart Rhythm</i> , 2010 , 7, 1862-9	6.7	42
112	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 13-28	7	232
111	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	9.5	3452
110	Risk factors and outcome of new-onset cardiac arrhythmias in vascular surgery patients. <i>American Heart Journal</i> , 2010 , 159, 1108-15	4.9	8
109	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>Europace</i> , 2010 , 12, 1360-420	3.9	1120
108	Ivabradine in patients with inappropriate sinus tachycardia. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010 , 382, 483-6	3.4	39
107	Cardiological evaluation after cerebral ischaemia : Consensus statement of the Working Group Heart and Brain of the German Cardiac Society-Cardiovascular Research (DGK) and the German Stroke Society (DSG). <i>Clinical Research in Cardiology</i> , 2010 , 99, 609-25	6.1	12
106	Coincidence of paroxysmal supraventricular tachycardia and panic disorder: two case reports. <i>Annals of General Psychiatry</i> , 2010 , 9, 13	3.4	4
105	Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. <i>Journal of Clinical Investigation</i> , 2010 , 120, 617-26	15.9	71
104	Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <i>Europace</i> , 2009 , 11, 860-85	3.9	84
103	Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence. <i>Europace</i> , 2009 , 11, 842-3	3.9	0
102	Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. <i>Europace</i> , 2009 , 11, 1338-44	3.9	43
101	Ca/calmodulin kinase II differentially modulates potassium currents. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009 , 2, 285-94	6.4	98
100	Indications for the use of diagnostic implantable and external ECG loop recorders. <i>Europace</i> , 2009 , 11, 671-87	3.9	238

99	Regional, age-dependent, and genotype-dependent differences in ventricular action potential duration and activation time in 410 Langendorff-perfused mouse hearts. <i>Basic Research in Cardiology</i> , 2009 , 104, 523-33	11.8	29
98	Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 401-7	2.7	56
97	Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 143-9	15.1	89
96	Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. <i>Europace</i> , 2009 , 11, 1362-8	3.9	50
95	"Zooming in" to new horizons: conduction abnormalities and other research perspectives in atrial fibrillation. <i>Heart Rhythm</i> , 2009 , 6, 1118-9	6.7	
94	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. <i>European Heart Journal</i> , 2009 , 30, 2969-77c	9.5	136
93	Diastolic isthmus length and 'vertical' isthmus angulation identify patients with difficult catheter ablation of typical atrial flutter: a pre-procedural MRI study. <i>Europace</i> , 2009 , 11, 42-7	3.9	24
92	The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. <i>Europace</i> , 2009 , 11, 423-34	3.9	263
91	Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. <i>EMBO Journal</i> , 2008 , 27, 692-703	13	91
90	Drugs that interact with cardiac electro-mechanics: old and new targets for treatment. <i>Progress in Biophysics and Molecular Biology</i> , 2008 , 97, 497-512	4.7	5
89	Detection of asymptomatic cerebral microbleeds: a comparative study at 1.5 and 3.0 T. <i>Academic Radiology</i> , 2008 , 15, 895-900	4.3	67
88	Data mining for detecting disturbances in heart rhythm 2008 ,		2
87	Survivin determines cardiac function by controlling total cardiomyocyte number. <i>Circulation</i> , 2008 , 117, 1583-93	16.7	93
86	Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation. <i>Europace</i> , 2008 , 10, 433-7	3.9	9
85	Electro-anatomic mapping systems in arrhythmias. <i>Europace</i> , 2008 , 10 Suppl 3, iii28-34	3.9	42
84	Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H1539-46	5.2	22
83	Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. <i>European Heart Journal</i> , 2008 , 29, 2125-32	9.5	229
82	Vorhofflimmern - eine Standortbestimmung - Vorkommen, Mechanismen und klinische Präsentation. <i>Klinikerzt</i> , 2008 , 37, 66-70	0	2

81	The German Competence Network on Atrial Fibrillation (AFNET). <i>Herz</i> , 2008 , 33, 548-55	2.6	7
80	Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. <i>Europace</i> , 2008 , 10, 21-7	3.9	98
79	New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2007 , 4, 790-3	6.7	9
78	Outcome parameters for trials in atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2007 , 28, 2803-17	9.5	267
77	Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <i>Europace</i> , 2007 , 9, 1006-23	3.9	197
76	Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, 962-71	5.8	19
75	Preclinical testing of drug-induced proarrhythmia: value of transgenic models. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2007 , 5, 289-94	1.9	4
74	Electrocardiographic risk stratification in families with congenital long QT syndrome. <i>European Heart Journal</i> , 2006 , 27, 2074-80	9.5	40
73	Hypertension begets hypertrophy begets atrial fibrillation? Insights from yet another sheep model. <i>European Heart Journal</i> , 2006 , 27, 2919-20	9.5	9
72	Approach to wide complex tachycardias in patients without structural heart disease. <i>Heart</i> , 2006 , 92, 704-11	5.1	16
71	Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. <i>Circulation</i> , 2006 , 114, 1799-806	16.7	321
70	Primary prevention of sudden cardiac death. <i>Heart</i> , 2006 , 92, 1873-8	5.1	21
69	G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. <i>Journal of Experimental Medicine</i> , 2006 , 203, 87-97	16.6	95
68	Semi-automated 3-dimensional intracardiac echocardiography: development and initial clinical experience of a new system to guide ablation procedures. <i>Heart Rhythm</i> , 2006 , 3, 1453-9	6.7	23
67	Ca ²⁺ /calmodulin-dependent protein kinase II regulates cardiac Na ⁺ channels. <i>Journal of Clinical Investigation</i> , 2006 , 116, 3127-38	15.9	397
66	A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). <i>European Heart Journal</i> , 2005 , 26, 1292-7	9.5	62
65	Cardiovert!--or better wait a little? Systematic evidence that the initial hours of atrial fibrillation are a "special time". <i>Heart Rhythm</i> , 2005 , 2, 1330-1	6.7	1
64	Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial. <i>American Heart Journal</i> , 2005 , 150, 899	4.9	16

63 Recording Monophasic Action Potentials **2005**, 417-431

62	Mechanism of catecholamine-induced ventricular tachycardias in mice with heart-directed expression of junctin and triadin: Shortening of action potentials and prolonged calcium transients. <i>Heart Rhythm</i> , 2005 , 2, S69	6.7	2
61	Introducing the German Mouse Clinic: open access platform for standardized phenotyping. <i>Nature Methods</i> , 2005 , 2, 403-4	21.6	148
60	Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?. <i>Herz</i> , 2005 , 30, 91-101	2.6	77
59	Gender differences in cardiac arrhythmias. <i>Herz</i> , 2005 , 30, 390-400	2.6	16
58	Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. <i>Basic Research in Cardiology</i> , 2005 , 100, 112-21	11.8	23
57	Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2005 , 26, 2422-34	9.5	613
56	Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice. <i>Journal of Biological Chemistry</i> , 2005 , 280, 6906-14	5.4	62
55	Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. <i>Cardiovascular Research</i> , 2004 , 62, 500-8	9.9	36
54	Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004 , 287, H2216-25	5.2	23
53	T wave alternans does not assess arrhythmic risk in patients with Brugada syndrome. <i>Annals of Noninvasive Electrocardiology</i> , 2004 , 9, 162-5	1.5	15
52	Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. <i>Journal of Cardiovascular Electrophysiology</i> , 2004 , 15, 1310-6	2.7	24
51	Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination. <i>Genesis</i> , 2004 , 39, 288-98	1.9	20
50	Pauses after burst pacing provoke afterdepolarizations and torsades de pointes in a patient with long QT syndrome. <i>Heart Rhythm</i> , 2004 , 1, 720-3	6.7	8
49	Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2004 , 36, 691-700	5.8	49
48	Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 257-63	4.7	48
47	Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. <i>Cardiovascular Research</i> , 2003 , 57, 1085-93	9.9	67
46	Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. <i>Cardiovascular Research</i> , 2003 , 59, 390-9	9.9	72

45	Effect of sotalol and acute ventricular dilatation on action potential duration and dispersion of repolarization after defibrillation shocks. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 41, 640-8	3.1	8
44	The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. <i>European Heart Journal</i> , 2003 , 24, 1104-12	9.5	135
43	Atrial fibrillation, thromboembolism, and haemostasis: causal or casual associations?. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 973-975	7	2
42	Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 285, H1453-53	5.3	47
41	Effect of electrode position on the outcome of cardioversion. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 292-6		6
40	Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. <i>Basic Research in Cardiology</i> , 2003 , 98, 25-32	11.8	67
39	Molekulare Mechanismen des plötzlichen Herztods und ihre klinische Bedeutung. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2003 , 14, 168-179	0.8	
38	Endocardial mapping of right ventricular outflow tract tachycardia using noncontact activation mapping. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 602-8	2.7	45
37	Incessant supraventricular tachycardia with constant 1:2 atrioventricular ratio: a longitudinally dissociated atrioventricular node?. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 316-9	2.7	10
36	Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 1027-33	2.7	104
35	In vivo recording of monophasic action potentials in awake dogs. <i>Methods</i> , 2003 , 30, 109-14	4.6	4
34	Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca ²⁺ -dependent action potential remodeling. <i>Circulation Research</i> , 2003 , 92, 428-36	15.7	130
33	A novel nonfluoroscopic catheter visualization system (LocaLisa) to reduce radiation exposure during catheter ablation of supraventricular tachycardias. <i>American Journal of Cardiology</i> , 2002 , 90, 340-3	3	33
32	Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2002 , 13, 742-9	2.7	50
31	Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 218-25	4.7	195
30	Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. <i>European Heart Journal</i> , 2002 , 23, 1394-401	9.5	66
29	Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. <i>Lancet, The</i> , 2002 , 360, 1275-9	4.0	164
28	Effects of thoracic epidural anesthesia with and without autonomic nervous system blockade on cardiac monophasic action potentials and effective refractoriness in awake dogs. <i>Anesthesiology</i> , 2001 , 95, 132-8; discussion 6A	4.3	41

27	Torsade de pointes induced by ajmaline. <i>Clinical Research in Cardiology</i> , 2001 , 90, 586-90		9
26	Load-induced changes in repolarization: evidence from experimental and clinical data. <i>Basic Research in Cardiology</i> , 2001 , 96, 369-80	11.8	32
25	Simultaneous in utero assessment of AV nodal and ventricular electrophysiologic parameters in the fetal sheep heart. <i>Basic Research in Cardiology</i> , 2001 , 96, 251-7	11.8	3
24	In vivo recording of monophasic action potentials in awake dogs--new applications for experimental electrophysiology. <i>Basic Research in Cardiology</i> , 2001 , 96, 169-74	11.8	5
23	Intracardiac tuberculoma causing "idiopathic" ventricular tachycardia in a patient without detectable heart disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , 12, 118	2.7	4
22	Brugada syndrome and supraventricular tachyarrhythmias: a novel association?. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , 12, 680-5	2.7	136
21	Clinical value of electrocardiographic parameters in genotyped individuals with familial long QT syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 406-15	1.6	9
20	Prolonged QRS duration increases QT dispersion but does not relate to arrhythmias in survivors of acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 789-95	1.6	10
19	Wolff-Parkinson-White syndrome associated with Brugada syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 1423-4	1.6	49
18	Clinical aspects of ventricular arrhythmias associated with QT prolongation. <i>European Heart Journal Supplements</i> , 2001 , 3, K81-K88	1.5	16
17	Genetic aspects in acquired long QT syndrome ? a piece in the puzzle. <i>European Heart Journal Supplements</i> , 2001 , 3, K48-K52	1.5	2
16	A patient with "atrial torsades de pointes". <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 806-11	2.7	27
15	Reproducible conversion from wide to narrow complex tachycardia: what is the mechanism?. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 941-3	2.7	
14	Modification of stretch-induced shortening of repolarization by streptomycin in the isolated rabbit heart. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, 711-21	3.1	31
13	Fetoscopic transesophageal electrocardiography and stimulation in fetal sheep: a minimally invasive approach aimed at diagnosis and termination of therapy-refractory supraventricular tachycardias in human fetuses. <i>Circulation</i> , 1999 , 100, 772-6	16.7	28
12	Transient local changes in right ventricular monophasic action potentials due to ajmaline in a patient with Brugada Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 1010-5	2.7	19
11	Phase angle convergence of multiple monophasic action potential recordings precedes spontaneous termination of ventricular fibrillation. <i>Basic Research in Cardiology</i> , 1998 , 93, 412-21	11.8	12
10	Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. <i>Circulation</i> , 1998 , 97, 2567-74	16.7	82

9	Shock-induced dispersion of ventricular repolarization: implications for the induction of ventricular fibrillation and the upper limit of vulnerability. <i>Journal of Cardiovascular Electrophysiology</i> , 1997 , 8, 998-1008	2.7	17
8	Induction of ventricular fibrillation by T-wave field-shocks in the isolated perfused rabbit heart: Role of nonuniform shock responses. <i>Basic Research in Cardiology</i> , 1997 , 92, 35-44	11.8	6
7	Myocardial vulnerability to T wave shocks: relation to shock strength, shock coupling interval, and dispersion of ventricular repolarization. <i>Journal of Cardiovascular Electrophysiology</i> , 1996 , 7, 231-42	2.7	63
6	Reduced arrhythmogenicity of biphasic versus monophasic T-wave shocks. Implications for defibrillation efficacy. <i>Circulation</i> , 1996 , 94, 1974-80	16.7	26
5	Computer analysis of monophasic action potentials: manual validation and clinically pertinent applications. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995 , 18, 1666-78	1.6	42
4	Pharmacology of Sudden Cardiac Death203-219		
3	Cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the heart		1
2	Clinical Trials on Atrial Fibrillation/Future Perspectives137-160		
1	Association of stroke lesion shape with newly detected atrial fibrillation [Results from the MonDAFIS study. <i>European Stroke Journal</i> ,239698732211008	5.6	